Date:	2/10/2022
Your Name:	Behzad Hajarizadeh
Manuscript Title:	Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales: a data linkage study
Manuscript Number (if known):	JHEPR-D-22-00032

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	 None The Kirby Institute is funded by the Australian Government Department of Health, under the agreement ID number 2-D3X513. This publication is part of the Bloodborne viruses and sexually transmissible infections Research, Strategic Interventions and Evaluation (BRISE) program, funded by the New South Wales Ministry of Health. 	
			Click the tab key to add additional rows.
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

		all entities with whom you have this nship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board,	None	

			es with whom you have this indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid			
11	Stock or stock options	⊠ None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None		
13	Other financial or non-financial interests	⊠ None		
Plea ×	Please place an "X" next to the following statement to indicate your agreement:			

Date:	2/10/2022
Your Name:	Gregory J. Dore
Manuscript Title:	Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales: a data linkage study
Manuscript Number (if known):	JHEPR-D-22-00032

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	 None The Kirby Institute is funded by the Australian Government Department of Health, under the agreement ID number 2-D3X513. This publication is part of the Bloodborne viruses and sexually transmissible infections Research, Strategic Interventions and Evaluation (BRISE) program, funded by the New South Wales Ministry of Health. GD is supported through an NHMRC of Australia Practitioner Fellowships. 	
			Click the tab key to add additional rows.
			,
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	 None GD has received research support from Gilead Sciences, Merck, and AbbVie. Other authors have no commercial 	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		relationships that might pose a conflict of interest in connection with this manuscript.	
3	Royalties or licenses	None	
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety	⊠ None	

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	-	e following statement to indicate your agreeme ered every question and have not altered the wo	

Date:	2/10/2022
Your Name:	Gail V. Matthews
Manuscript Title:	Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales: a data linkage study
Manuscript Number (if known):	JHEPR-D-22-00032

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	Name all entities with whom you have thisSpecifications/Comments (e.g., if paysrelationship or indicate none (add rows as needed)made to you or to your institution)		Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	 None The Kirby Institute is funded by the Australian Government Department of Health, under the agreement ID number 2-D3X513. This publication is part of the Bloodborne viruses and sexually transmissible infections Research, Strategic Interventions and Evaluation (BRISE) program, funded by the New South Wales Ministry of Health. 	Click the tab key to add additional rows.
		Time frame: past 36 months	5
2	Grants or contracts from any entity (if not indicated in item #1 above).	 None GM has received research support from Gilead Sciences and AbbVie. 	

		all entities with whom you have this nship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board,	None	

		ne all entities with whom you have this Specifications/Commutionship or indicate none (add rows as needed) made to you or to you	ents (e.g., if payments were ir institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		

Date: 2/10/2022	
Your Name:	Syed Hassan Bin Usman Shah
Manuscript Title:	Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales: a data linkage study
Manuscript Number (if known):	JHEPR-D-22-00032

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	 None The Kirby Institute is funded by the Australian Government Department of Health, under the agreement ID number 2-D3X513. This publication is part of the Bloodborne viruses and sexually transmissible infections Research, Strategic Interventions and Evaluation (BRISE) program, funded by the New South Wales Ministry of Health. 	Click the tab key to add additional rows.
		Time frame: past 36 months	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

		all entities with whom you have this nship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board,	None	

			es with whom you have this indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid			
11	Stock or stock options	⊠ None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None		
13	Other financial or non-financial interests	⊠ None		
Plea ×	Please place an "X" next to the following statement to indicate your agreement:			

Date:	2/10/2022
Your Name:	Heather Valerio
Manuscript Title:	Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales: a data linkage study
Manuscript Number (if known):	JHEPR-D-22-00032

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	 None The Kirby Institute is funded by the Australian Government Department of Health, under the agreement ID number 2-D3X513. This publication is part of the Bloodborne viruses and sexually transmissible infections Research, Strategic Interventions and Evaluation (BRISE) program, funded by the New South Wales Ministry of Health. 	Click the tab key to add additional rows.
		Time frame: past 36 months	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

		all entities with whom you have this nship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board,	None	

			es with whom you have this indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid			
11	Stock or stock options	⊠ None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None		
13	Other financial or non-financial interests	⊠ None		
Plea ×	Please place an "X" next to the following statement to indicate your agreement:			

Date:	2/10/2022
Your Name:	Janaki Amin
Manuscript Title:	Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales: a data linkage study
Manuscript Number (if known):	JHEPR-D-22-00032

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

Name all entities with whom you have this relationship or indicate none (add rows as needed)		-	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☑ None	Click the tab key to add additional rows.	
		Time frame: past 36 month	ns	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None		
3	Royalties or licenses	None		

		Name all entities with whom you have thisSpecifications/Comments (e.g., if paymentsrelationship or indicate none (add rows as needed)made to you or to your institution)	were
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☑ None □ □ □ □ □ □	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑ None	
13	Other financial or non-financial interests	None	
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	2/10/2022
Your Name:	Jacob George
Manuscript Title:	Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales: a data linkage study
Manuscript Number (if known):	JHEPR-D-22-00032

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
 All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. J George is supported by an I Australia Program Grant (109 project grants (632630, 1049 NHMRC Practitioner Fellows) West Translational Cancer Recentre grant funded by the Constitute New South Wales, and Robert W. Storr Bequest to the set of the se		J George is supported by an NHMRC of Australia Program Grant (1053206), project grants (632630, 1049857), a NHMRC Practitioner Fellowship, a Sydney West Translational Cancer Research Centre grant funded by the Cancer Institute New South Wales, and the Robert W. Storr Bequest to the Sydney Medical Foundation, University of	Click the tab key to add additional rows.
		Time frame: past 36 months	S
2	Grants or contracts from any entity (if not	□ None	
	indicated in item #1 above).	J George is on the speaker's bureau for Gilead Sciences, Merck, Janssen, Roche, and Pharmaxis. J George is a member of advisory board for Gilead Sciences,	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Merck, Janssen, Bristol-Myers Squibb, AbbVie, Roche, GlaxoSmithKline, Pharmaxis and Pfizer. J George has received travel support from Gilead Sciences, Merck, Bristol-Myers Squibb, AbbVie, and Roche.	
3	Royalties or licenses	None	
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	☑ None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	⊠ None	

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea		e following statement to indicate your agreeme ered every question and have not altered the wo	

Date:	2/10/2022
Your Name:	Maryam Alavi
Manuscript Title:	Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales: a data linkage study
Manuscript Number (if known):	JHEPR-D-22-00032

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	 None The Kirby Institute is funded by the Australian Government Department of Health, under the agreement ID number 2-D3X513. This publication is part of the Bloodborne viruses and sexually transmissible infections Research, Strategic Interventions and Evaluation (BRISE) program, funded by the New South Wales Ministry of Health. 	Click the tab key to add additional rows.
		Time frame: past 36 months	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

		all entities with whom you have this nship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board,	None	

			es with whom you have this indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid			
11	Stock or stock options	⊠ None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None		
13	Other financial or non-financial interests	⊠ None		
Plea ×	Please place an "X" next to the following statement to indicate your agreement:			

Date:	2/10/2022
Your Name:	Mark Danta
Manuscript Title:	Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales: a data linkage study
Manuscript Number (if known):	JHEPR-D-22-00032

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	⊠ None	Click the tab key to add additional rows.
		Time frame: past 36 mont	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	⊠ None	

		Name all entities with whom you have thisSpecifications/Comments (e.g., if paymentsrelationship or indicate none (add rows as needed)made to you or to your institution)	were
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☑ None □ □ □ □ □ □	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑ None	
13	Other financial or non-financial interests	None	
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	2/10/2022	
Your Name:	Matthew G. Law	
Manuscript Title:	Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales: a data linkage study	
Manuscript Number (if known):	JHEPR-D-22-00032	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	 None The Kirby Institute is funded by the Australian Government Department of Health, under the agreement ID number 2-D3X513. This publication is part of the Bloodborne viruses and sexually transmissible infections Research, Strategic Interventions and Evaluation (BRISE) program, funded by the New South Wales Ministry of Health. 	
	Click the ta		Click the tab key to add additional rows.
		Time frame: past 36 months	S
2	Grants or contracts from	□ None	
	any entity (if not indicated in item #1 above).	ML has received research support from Merck, Bristol-Myers Squibb, Boehringer Ingelheim, Janssen-Cilag, Gilead Sciences, and ViiV HealthCare. ML has received consultancy and workshop fees from	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Gilead Sciences. ML has received Data Safety Monitoring Board Committee fees from Sirtex Pty Ltd.	
3	Royalties or licenses	☑ None	
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety	⊠ None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Monitoring Board or Advisory Board			
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid		None	
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			

Date:	2/10/2022	
Your Name:	Marianne Martinello	
Manuscript Title:	Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales: a data linkage study	
Manuscript Number (if known):	JHEPR-D-22-00032	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

1 All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) None No time limit for this item. The Kirby Institute is funded by the Australian Government Department of Health, under the agreement ID number 2-D3X513. This publication is part of the Bloodborne viruses and sexually transmissible infections Research, Strategic Interventions and Evaluation (BRISE) program, funded by the New South Wales Ministry of Health. MM is supported by an NHMRC Early Career Fellowship. Click the tab key to add additional rows.		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)The Kirby Institute is funded by the Australian Government Department of Health, under the agreement ID number 2-D3X513. This publication is part of the Bloodborne viruses and sexually transmissible infections Research, Strategic Interventions and Evaluation (BRISE) program, funded by the New South Wales Ministry of Health. MM is supported by an NHMRC Early Career Fellowship.		Time frame: Since the initial planning	of the work
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	The Kirby Institute is funded by the Australian Government Department of Health, under the agreement ID number 2-D3X513. This publication is part of the Bloodborne viruses and sexually transmissible infections Research, Strategic Interventions and Evaluation (BRISE) program, funded by the New South Wales Ministry of Health. MM is supported by an NHMRC Early Career	Click the tab key to add additional rows.

			all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
2	Grants or contracts from any entity (if not indicated in item #1 above).		None	
3	Royalties or licenses		None	
4	Consulting fees		None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events		None	
6	Payment for expert testimony		None	
7	Support for attending meetings and/or travel		None	
8	Patents planned, issued or pending		None	
9	Participation on a Data Safety	\boxtimes	None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Monitoring Board or Advisory Board			
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid		None	
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			